American Century Companies Inc. Has $816.40 Million Position in Pfizer (PFE)

American Century Companies Inc. lifted its position in shares of Pfizer (NYSE:PFE) by 46.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,539,888 shares of the biopharmaceutical company’s stock after acquiring an additional 7,161,892 shares during the period. Pfizer makes up approximately 0.8% of American Century Companies Inc.’s portfolio, making the stock its 15th largest position. American Century Companies Inc. owned approximately 0.38% of Pfizer worth $816,395,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Americafirst Capital Management LLC purchased a new position in shares of Pfizer during the 3rd quarter worth $127,000. Delphi Private Advisors LLC lifted its stake in shares of Pfizer by 84.3% during the 4th quarter. Delphi Private Advisors LLC now owns 3,499 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 1,600 shares in the last quarter. Lipe & Dalton lifted its stake in shares of Pfizer by 6.9% during the 2nd quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 300 shares in the last quarter. Legacy Advisors LLC purchased a new position in shares of Pfizer during the 3rd quarter valued at $164,000. Finally, Oak Point Wealth Management purchased a new position in shares of Pfizer during the 4th quarter valued at $165,000. 71.19% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

In related news, insider Douglas M. Lankler sold 50,000 shares of Pfizer stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $36.89, for a total transaction of $1,844,500.00. Following the completion of the transaction, the insider now directly owns 133,057 shares of the company’s stock, valued at approximately $4,908,472.73. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Rady A. Johnson sold 27,323 shares of Pfizer stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $36.55, for a total transaction of $998,655.65. Following the transaction, the executive vice president now directly owns 70,332 shares of the company’s stock, valued at $2,570,634.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 248,037 shares of company stock valued at $9,064,785. 0.06% of the stock is owned by corporate insiders.

Pfizer stock opened at $36.49 on Thursday. Pfizer has a twelve month low of $31.67 and a twelve month high of $39.43. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.10 and a current ratio of 1.35. The stock has a market capitalization of $217,458.14, a PE ratio of 13.77, a price-to-earnings-growth ratio of 1.83 and a beta of 0.90.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The firm had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. During the same period in the previous year, the company earned $0.47 EPS. The firm’s revenue for the quarter was up .6% compared to the same quarter last year. equities analysts forecast that Pfizer will post 2.95 earnings per share for the current fiscal year.

PFE has been the topic of a number of analyst reports. SunTrust Banks restated a “hold” rating and set a $40.00 target price (up previously from $33.00) on shares of Pfizer in a research note on Monday, January 29th. Jefferies Group set a $39.00 price target on shares of Pfizer and gave the company a “hold” rating in a report on Monday, February 26th. Morningstar set a $38.00 price target on shares of Pfizer and gave the company a “neutral” rating in a report on Tuesday, January 30th. BMO Capital Markets set a $43.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, March 6th. Finally, Vetr downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $37.98 price target on the stock. in a report on Monday, January 15th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $39.20.

TRADEMARK VIOLATION WARNING: This news story was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.thelincolnianonline.com/2018/04/19/american-century-companies-inc-has-816-40-million-position-in-pfizer-pfe.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply